ImmuPharma (LON:IMM) Trading Down 8.3% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price traded down 8.3% during mid-day trading on Wednesday . The company traded as low as GBX 4.11 ($0.05) and last traded at GBX 4.59 ($0.06). 7,864,863 shares were traded during trading, a decline of 65% from the average session volume of 22,321,723 shares. The stock had previously closed at GBX 5 ($0.06).

ImmuPharma Trading Up 23.8 %

The firm has a market cap of £20.11 million, a P/E ratio of -483.00 and a beta of 1.53. The business’s fifty day moving average price is GBX 2.46 and its two-hundred day moving average price is GBX 1.95.

ImmuPharma Company Profile

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.